| Similar Articles |
|---|
 |
The Motley Fool
October 15, 2009
Robert Steyer |
Little Discord on Acorda Drug FDA advisory panel overwhelmingly backs a drug to improve the walking ability of multiple sclerosis patients.   |
The Motley Fool
June 8, 2010
Brian Orelli |
Injecting Uncertainty Into the Multiple Sclerosis Market Novartis' oral MS drug could be a blockbuster -- if it can get past the FDA. |
The Motley Fool
January 25, 2010
Brian Orelli |
No Way to Hide This Drug Approval FDA trumps Acorda on its good news. The biotech announced Food and Drug Administration approval of Ampyra, its drug to help multiple sclerosis patients walk better after the markets closed on Friday. |
The Motley Fool
September 23, 2010
Brian Orelli |
A Blockbuster in Due Time Novartis' new multiple sclerosis drug, Gilenya, isn't king yet. |
The Motley Fool
March 3, 2011
Brian Orelli |
3 Cheers for an FDA Rejection German drugmaker Merck said that the Food and Drug Administration had turned down its multiple sclerosis drug cladribine. The pill would have competed with Novartis' Gilenya, which gained FDA approval last year. |
The Motley Fool
June 11, 2010
Brian Orelli |
25 to 0! Now That's a Ringing Endorsement Novartis flies through its advisory panel meeting nearly unscathed. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
September 9, 2010
Brian Orelli |
Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September. |
The Motley Fool
May 26, 2010
Brian Orelli |
Blockbuster Drugs Aimed at Busting MS Multiple sclerosis is a large market with more entrants coming. |
The Motley Fool
February 10, 2010
Brian Orelli |
Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause. |
The Motley Fool
November 29, 2010
Brian Orelli |
There's Still Only One Merck KGaA's oral MS drug delay is Novartis' gain. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
September 22, 2010
Jordan DiPietro |
A Huge Victory for Novartis MS oral drug is approved. |
The Motley Fool
July 2, 2009
Brian Orelli |
Deal Struck, Shares Stuck Acorda Therapeutics secured a decent upfront payment to license the ex-U.S. rights to its multiple sclerosis drug, Fampridine-SR, from the perfect partner. Unfortunately, investors still smacked the stock down nearly 15% yesterday. |
The Motley Fool
April 22, 2011
MedCity News |
Biogen Idec's MS Drug Appears to Have an Edge Trial results give the company an advantage in oral MS treatments. |
The Motley Fool
June 3, 2008
Brian Orelli |
Taking a Walk With a 10-Bagger Acorda Therapeutics gets it done with phase 3 trial data on a new MS drug. |
The Motley Fool
January 31, 2007
Brian Lawler |
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
June 29, 2010
Brian Orelli |
The Final Obstacle to Your Drug Company Multibagger The dreaded FDA advisory committee meeting. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
June 23, 2011
Brian Orelli |
One Less Oral MS Drug to Worry About But competition is still tough. |
The Motley Fool
October 27, 2010
Brian Orelli |
Biogen Idec's Fight-Back Plan Novartis' Gilenya is coming, but Biogen has a backup plan. |
The Motley Fool
August 1, 2007
Brian Lawler |
Elan Gets a Vote of Confidence Elan receives some good news from an FDA advisory panel in the form of a recommendation to expand the use of Tysabri to treat Crohn's disease. |
The Motley Fool
December 9, 2010
Brian Orelli |
Here Comes Another Oral MS Drug Good for Teva, bad for the rest. |
The Motley Fool
November 18, 2008
Brian Orelli |
Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
November 1, 2010
Brian Orelli |
Stock Doubles! No Crying Here AVANIR Pharmaceuticals' investors didn't have any uncontrolled crying on Friday when the Food and Drug Administration approved Nuedexta, the company's treatment for pseudobulbar affect. |
The Motley Fool
October 31, 2011
Brian Orelli |
When You've Got It, You've Got It Biogen keeps its good-news streak going. |
The Motley Fool
July 27, 2010
Brian Orelli |
Branded? Generic? They're Both Doing Great! Teva Pharmaceuticals registers strong growth on both fronts. |
The Motley Fool
July 17, 2009
Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool
August 26, 2008
Brian Lawler |
FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs. |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
The Motley Fool
September 25, 2007
Brian Lawler |
Acorda at a Glance Acorda Therapeutics has given astute biotech investors quite a ride over the last 12 months following positive results for their lead drug, Fampridine-SR. That drug now takes another step towards FDA approval. Investors, take note. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
The Motley Fool
September 30, 2009
Brian Orelli |
Less Is More for Novartis That makes it simple enough. |
The Motley Fool
February 2, 2011
Brian Orelli |
A Deeper Dive Into Biogen's Revenue Growth On the surface, it looks like Biogen Idec is handling the entrance of Novartis' new oral multiple sclerosis drug, Gilenya, quite well. The real picture is a little bleaker. |
The Motley Fool
December 7, 2004
Charly Travers |
Spin the Medicine Bottle Is a new MS drug going to be a top seller or a bottom-dweller? Here's how to find out. Before investing in any pharmaceutical company with a product in development, go through this exercise to estimate the new drug's potential. |
The Motley Fool
October 5, 2006
Brian Lawler |
Elan Extends Tysabri's Reach The MS-fighting drug gains approval in Canada. Next month, when Biogen and Elan report third-quarter results, investors will get a preliminary indication of how these sales of Tysabri are ramping up. |
The Motley Fool
December 6, 2005
Stephen D. Simpson |
Tysabri Tries Again Will the FDA finally approve Elan's multiple sclerosis drug? Investors' fingers are crossed. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
October 19, 2010
Brian Orelli |
Why the FDA Won't Approve Lorcaserin and Qnexa (Yet) Obesity drugs get their day in front of the agency. |
Pharmaceutical Executive
November 1, 2008
Jim Wahl |
The Mess in MS A five-year forecast of the multiple-sclerosis market following the disruptions of Tysabri. |
The Motley Fool
January 16, 2008
Brian Lawler |
More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note. |
The Motley Fool
May 12, 2011
Brian Orelli |
Teva's Mixed Bag Diversification sure helps. |
The Motley Fool
June 25, 2010
Brian Orelli |
Mark Your Calendars: Obesity Drugs Take Center Stage Orexigen Therapeutics has been given an FDA advisory committee meeting date, completing the dates for the trio of obesity drugs up for review. |
The Motley Fool
May 26, 2005
Stephen D. Simpson |
Elan Holds Its Ground Elan clearly isn't throwing in the towel on Tysabri, but its fate is not solely in the company's hands. If you're pinning your hopes on a full return on this drug, you might be signing on for more risk than you really want. |
The Motley Fool
September 22, 2009
Robert Steyer |
Will Teva Be Forced to Take Its Own Medicine? Teva's biggest source of revenue and profit, the multiple sclerosis drug Copaxone, is facing a patent challenge. |
The Motley Fool
February 7, 2008
Brian Lawler |
Biogen Rests Rumors The pharmaceutical announces its year-end financial results, and squashes rumors that it is considering a major acquisition. |
The Motley Fool
June 18, 2007
Billy Fisher |
Elan Elevates Its Game New drug prospects push the Dublin-based biotech's shares to a new 52-week high. |
The Motley Fool
May 5, 2010
Brian Orelli |
Teva's Double-Edged Sword Nice quarter, but where will future growth come from? |
